Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Published:2023-02 Issue:2 Volume:24 Page:139-150
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dytfeld Dominik,Wróbel Tomasz,Jamroziak Krzysztof,Kubicki Tadeusz,Robak Paweł,Walter-Croneck Adam,Czyż Jarosław,Tyczyńska Agata,Druzd-Sitek Agnieszka,Giannopoulos Krzysztof,Nowicki Adam,Szczepaniak Tomasz,Łojko-Dankowska Anna,Matuszak Magdalena,Gil Lidia,Puła Bartosz,Rybka Justyna,Majcherek Maciej,Usnarska-Zubkiewicz Lidia,Szukalski Łukasz,Końska Agnieszka,Zaucha Jan Maciej,Walewski Jan,Mikulski Damian,Czabak Olga,Robak Tadeusz,Lahoud Oscar B,Zonder Jeffrey A,Griffith Kent,Stefka Andrew,Major Ajay,Derman Benjamin A,Jakubowiak Andrzej J

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma;Attal;Blood,2006

2. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial;Jackson;Lancet Oncol,2019

3. Lenalidomide after stem-cell transplantation for multiple myeloma;McCarthy;N Engl J Med,2012

4. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma;Attal;N Engl J Med,2012

5. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis;McCarthy;J Clin Oncol,2017

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An ATLAS to map MRD with peripheral blood;Blood;2024-08-29

2. Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma;Blood;2024-08-29

3. Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs;Clinical and Experimental Medicine;2024-08-06

4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial;The Lancet Oncology;2024-08

5. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27